Literature DB >> 17532855

Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised?

Gianluca Giannarini1, Martin C Schumacher, George N Thalmann, Alain Bitton, Achim Fleischmann, Urs E Studer.   

Abstract

OBJECTIVE: To determine the long-term oncological outcome of patients with primary transitional cell carcinoma (TCC) of the distal ureter electively treated with either kidney-sparing surgery (KSS) or radical nephroureterectomy (RNU) in a retrospective, non-randomized, single-centre study. PATIENTS AND METHODS: Of 43 consecutive patients with a primary solitary distal ureter TCC, 19 had KSS, consisting of distal ureter resection with bladder cuff excision and ureter reimplantation, and 24 had RNU with bladder cuff excision.
RESULTS: The median (range) age at surgery was 69 (31-86) years for the KSS group and 73 (59-87) years for the RNU group, patients in the latter having worse hydronephrotic kidneys. The median (range) follow-up was 58 (3-260) months. A recurrent bladder tumour was diagnosed after a median of 15 months in five of the 19 patients treated by KSS and after a median of 5.5 months in eight of the 24 treated by RNU. Five of the 19 patients treated by KSS and six of the 24 treated by RNU died from metastatic disease despite chemotherapy. Recurrence-free, cancer-specific and overall survival were comparable in the two groups. In two patients (11%) treated by KSS an ipsilateral upper urinary tract TCC recurred after 42 and 105 months, respectively.
CONCLUSION: Treatment by distal ureteric resection is feasible in patients with primary TCC of the distal ureter. The long-term oncological outcome seems to be comparable with that of patients treated by RNU. Furthermore, kidney preservation is advantageous if adjuvant or salvage chemotherapy is required.

Entities:  

Mesh:

Year:  2007        PMID: 17532855     DOI: 10.1111/j.1464-410X.2007.06993.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  12 in total

1.  Correlation between surgical modality and clinicopathologic characteristics for ureteral transitional cell carcinoma.

Authors:  S Bing-bing; C Cheng; L Han-zhong; R Shi; H Zhong-ming; F Hua; W Jin; W Qing-hai; J Zhi-gang; F Yujiang
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  A 79-year-old man with urothelial carcinoma of the bladder and upper urinary tract.

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

3.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Tomonori Kato; Ryo Nakayama; Tomomi Haba; Makoto Kawaguchi; Akira Komiya; Hiroshi Koike
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

Review 4.  Nephron-sparing Management of Upper Tract Urothelial Carcinoma.

Authors:  Francesca Suriano; Tommaso Brancato
Journal:  Rev Urol       Date:  2014

5.  A patient with synchronous bilateral low-grade upper tract urothelial carcinoma who underwent nephroureterectomy and total ureterectomy with ileal ureteric replacement.

Authors:  Yoshinori Matsuda; Takamitsu Inoue; Atsushi Maeno; Atsushi Koizumi; Ryohei Yamamoto; Taketoshi Nara; Sohei Kanda; Kazuyuki Numakura; Mitsuru Saito; Shintaro Narita; Shigeru Satoh; Tomonori Habuchi
Journal:  Int Cancer Conf J       Date:  2020-03-03

Review 6.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

7.  Oncologic outcomes and prognostic impact of urothelial recurrences in patients undergoing segmental and total ureterectomy for upper tract urothelial carcinoma.

Authors:  Jose A Pedrosa; Timothy A Masterson; Kevin R Rice; Hristos Z Kaimakliotis; M Francesca Monn; Richard Bihrle; Michael O Koch; Ronald S Boris
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 8.  [Endosopic organ-sparing treatment of urothelial tumors of the upper urinary tract: indications and results].

Authors:  M Hruza; C Stock; D Teber; J J Rassweiler
Journal:  Urologe A       Date:  2008-07       Impact factor: 0.639

9.  Conservative nephron-sparing treatment of upper-tract tumors.

Authors:  Paul Smith; Juliette Mandel; Jay D Raman
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

Review 10.  A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  D Fang; T Seisen; K Yang; P Liu; X Fan; N Singla; G Xiong; L Zhang; X Li; L Zhou
Journal:  Eur J Surg Oncol       Date:  2016-08-25       Impact factor: 4.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.